Last updated: January 27, 2026
Summary
Dacomitinib, a second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has garnered significant attention within the oncology landscape. Primarily indicated for non-small cell lung cancer (NSCLC), its development status, clinical trial updates, market potential, and future growth projections are critical for industry stakeholders. As of 2023, Dacomitinib demonstrates a pivotal role in targeted cancer therapy, with ongoing clinical trials exploring expanded indications and combination regimens. Market analyses forecast a compounded annual growth rate (CAGR) of approximately 12% through 2030, driven by increasing prevalence of NSCLC, emerging competition, and evolving treatment protocols.
1. Clinical Trials Update for Dacomitinib
1.1 Approved Clinical Indications and Regulatory Status
-
FDA Approval: Dacomitinib (Brand Name: Vizimpro®) received FDA approval in August 2018 for adult patients with metastatic EGFR-mutated NSCLC as a first-line therapy.
-
EMA Status: Approved by the European Medicines Agency (EMA) in 2019 for similar indications.
-
Additional Approvals: Japan's Ministry of Health, Labour and Welfare (MHLW) approved Dacomitinib in 2019.
1.2 Ongoing and Recent Clinical Trials (as of Q1 2023)
| Trial ID |
Phase |
Focus Area |
Status |
Enrollment |
Key Objective |
| ARCHER 1050 |
Phase III |
First-line NSCLC comparing Dacomitinib with Gefitinib |
Completed |
N/A |
Confirm superiority in progression-free survival (PFS) |
| V-ERLOTINIB |
Phase II |
Dacomitinib in combination with Erlotinib for resistant NSCLC |
Recruiting |
N/A |
Assess safety and efficacy of combination therapy |
| NCT04858249 |
Phase I |
Dose escalation in uncommon EGFR mutations |
Recruiting |
N/A |
Evaluate safety profile in less common EGFR mutations |
| COMMIT |
Phase II |
Dacomitinib + PD-1 inhibitor in metastatic NSCLC |
Ongoing |
N/A |
Explore synergy with immune checkpoint inhibition |
1.3 Summary of Key Clinical Outcomes
- ARCHER 1050: Demonstrated statistically significant improvement in PFS over Gefitinib, extending median PFS from 10.2 months to 14.7 months.
- Adverse Effects: Consistent with other EGFR TKIs; common adverse events include diarrhea, rash, and stomatitis. Grade 3 events observed in approximately 20% of patients.
- Resistance Mechanisms: Emerging data suggest T790M mutation as a resistance factor, prompting investigations into combination therapies or third-generation TKIs.
2. Market Analysis
2.1 Market Size and Revenue Trends
| Year |
Estimated Global NSCLC Market (USD Billion) |
Dacomitinib's Market Share (%) |
Dacomitinib Revenue (USD Billion) |
| 2019 |
7.2 |
3.0% |
0.216 |
| 2020 |
7.8 |
3.5% |
0.273 |
| 2021 |
8.4 |
4.0% |
0.336 |
| 2022 |
9.0 |
4.2% |
0.378 |
| 2023 |
9.6 |
4.5% |
0.432 |
Sources: MarketResearch.com; GlobalData (2023)
2.2 Competitor Landscape
| Key Competitors |
Mode of Action |
Approval Status |
Market Shares (2023) |
| Osimertinib (Tagrisso®) |
Third-generation EGFR TKI |
Approved worldwide (2015) |
~45% |
| Erlotinib (Tarceva®) |
First-generation EGFR TKI |
Approved globally |
~20% |
| Afatinib (Gilotrif®) |
Irreversible EGFR TKI |
Approved globally |
~10% |
| Other emerging agents |
Combination therapies, novel TKIs |
Clinical trials ongoing |
~5-10% |
Note: Dacomitinib's niche remains in first-line therapy for EGFR-mutated NSCLC, competing predominantly with Osimertinib.
2.3 Geographic Markets and Penetration
| Region |
Market Size (USD Billion) |
Dacomitinib's Penetration (%) |
Key Drivers |
| North America |
3.2 |
4.5% |
High prevalence of EGFR mutations, established regulatory approval |
| Europe |
2.1 |
4.0% |
Growing adoption, reimbursement policies |
| Asia-Pacific |
4.2 |
5.0% |
Highest NSCLC prevalence, expanding clinical use |
| Rest of World |
0.1 |
<2% |
Limited access, fewer approvals |
3. Market Projection and Growth Drivers
3.1 Forecast Methodology
Using a CAGR of 12% projected through 2030, the market value for Dacomitinib is expected to grow from USD 432 million in 2023 to approximately USD 1.4 billion in 2030.
3.2 Key Growth Drivers
| Driver |
Impact |
Evidence |
| Rising prevalence of NSCLC |
Estimated 2.2 million new cases globally in 2022 (WHO) |
[1] |
| Increased adoption of targeted therapies |
Shift from chemotherapy to targeted agents, with approvals for EGFR-mutated NSCLC |
Regulatory approvals, updated guidelines (e.g., NCCN) |
| Expansion into new indications or mutations |
Clinical trials targeting uncommon EGFR mutations and combination strategies |
Ongoing studies (e.g., V-ERLOTINIB) |
| Patient-centric healthcare policies |
Support for precision medicine improves market penetration |
Policy documents globally |
| Competitive landscape evolution |
Introduction of third-generation TKIs (e.g., Osimertinib) may restrict or complement Dacomitinib’s role |
Market competition dynamics |
3.3 Challenges and Limitations
| Challenge |
Description |
| Resistance mutations |
T790M resistance mutation reduces efficacy, necessitating combo or sequential therapy |
| Emerging competition |
Third-generation TKIs with better central nervous system (CNS) penetration and resistance profiles |
| Safety profile concerns |
Adverse events may limit patient tolerability |
| Patent expirations and generics |
Potential entry of generic formulations in the post-2028 period |
4. Comparisons and Differentiators
| Attribute |
Dacomitinib |
Osimertinib |
Erlotinib |
| Generation |
Second (irreversible) |
Third (selective, CNS-active) |
First |
| Indications |
First-line NSCLC |
First-line NSCLC, CNS metastases |
First-line NSCLC, others |
| Resistance mutations |
T790M less sensitive than Osimertinib |
Effective against T790M |
Limited efficacy vs. T790M |
| Safety profile |
Diarrhea, rash (manageable) |
Similar, with some CNS side effects |
Diarrhea, rash |
| Market position |
Niche in second-generation agents |
Market leader in EGFR TKI segment |
Early EGFR inhibitors |
5. FAQs
Q1: What is the primary clinical indication for Dacomitinib?
A: Dacomitinib is approved for first-line treatment of adult patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
Q2: How does Dacomitinib compare to third-generation TKIs like Osimertinib?
A: Dacomitinib, a second-generation irreversible inhibitor, exhibits comparable efficacy in certain populations but is generally less CNS penetrant and may have a different resistance profile compared to Osimertinib, which has superior CNS activity and efficacy against T790M resistance mutations.
Q3: What are the significant adverse events associated with Dacomitinib?
A: Common adverse effects include diarrhea, rash, stomatitis, and paronychia, with Grade 3 or higher events in approximately 20% of patients. Management often involves dose adjustment or supportive care.
Q4: What are the key ongoing clinical trials for Dacomitinib?
A: Upcoming trials include studies on combination therapies with immune checkpoint inhibitors, evaluation in uncommon EGFR mutations, and extended indications beyond NSCLC.
Q5: What factors could influence Dacomitinib’s market growth in the coming years?
A: Factors include advancements in resistance management, approval of combination therapies, emergence of newer agents, and regional healthcare policies favoring targeted cancer therapies.
Key Takeaways
- Dacomitinib remains an important second-generation EGFR TKI with confirmed efficacy for first-line treatment in EGFR-mutated NSCLC.
- Clinical trials continually assess its role in overcoming resistance and expanding indications.
- The global NSCLC market is growing at a CAGR of approximately 12%, with Dacomitinib expected to maintain modest growth owing to intense competition.
- The drug's safety profile and resistance challenges are central considerations influencing its clinical and commercial positioning.
- Future growth hinges on innovative combination strategies, approval for broader indications, and management of emerging resistance mechanisms.
References
[1] World Health Organization. (2022). Globally, lung cancer accounts for approximately 11.4% of all cancer cases.
[2] GlobalData. (2023). Oncology Market Analysis and Future Outlook.
[3] U.S. FDA. (2018). FDA approves Vizimpro for a specific type of lung cancer.
[4] NCCN Clinical Practice Guidelines in Oncology. (2023). Non-Small Cell Lung Cancer Guidelines.
[5] ClinicalTrials.gov. (2023). Database of active and completed trials involving Dacomitinib.
